|
ATP2B1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.44880046532614E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4423000016528E-08 |
| Normal-vs-Stage2 |
7.94030000000889E-05 |
| Normal-vs-Stage3 |
2.7975999294938E-10 |
| Normal-vs-Stage4 |
5.81689999945567E-07 |
| Stage1-vs-Stage2 |
8.679600E-01 |
| Stage1-vs-Stage3 |
1.075620E-01 |
| Stage1-vs-Stage4 |
6.372200E-01 |
| Stage2-vs-Stage3 |
3.754600E-01 |
| Stage2-vs-Stage4 |
8.112600E-01 |
| Stage3-vs-Stage4 |
5.061400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.29070004368282E-09 |
| Normal-vs-AfricanAmerican |
4.06129999996896E-06 |
| Normal-vs-Asian |
2.364899998053E-08 |
| Caucasian-vs-AfricanAmerican |
4.551600E-01 |
| Caucasian-vs-Asian |
4.072000E-01 |
| AfricanAmerican-vs-Asian |
8.936200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.51040005134251E-09 |
| Normal-vs-Female |
2.74529998733897E-09 |
| Male-vs-Female |
4.926800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.05329994620962E-09 |
| Normal-vs-Age(41-60Yrs) |
1.69750002942948E-09 |
| Normal-vs-Age(61-80Yrs) |
1.10540000486381E-08 |
| Normal-vs-Age(81-100Yrs) |
7.613600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.846400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.169000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.032400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.944200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.027200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.254800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.599400E-01 |
| Classical-VS-Follicular |
5.434700E-04 |
| Classical-VS-Other |
4.234600E-01 |
| Classical-VS-Normal |
1.57849999999904E-05 |
| Tall-VS-Follicular |
1.782610E-01 |
| Tall-VS-Other |
7.144200E-01 |
| Tall-VS-Normal |
1.92538000000075E-05 |
| Follicular-VS-Other |
7.180000E-01 |
| Follicular-VS-Normal |
1.69879665889994E-11 |
| Other-VS-Normal |
4.115400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.45220502290044E-11 |
| Normal-vs-N1 |
1.802370E-03 |
| N0-vs-N1 |
5.148200E-01 |
|
|
